<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RIVASTIGMINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RIVASTIGMINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild to moderate dementia in Alzheimer's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By transdermal application using patches</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily, dose to be increased at intervals of at least 2 weeks according to response and tolerance; usual dose 3&#8211;6 mg twice daily (max. per dose 6 mg twice daily), if treatment interrupted for more than several days, retitrate from 1.5 mg twice daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 4.6 mg/24 hours daily for at least 4 weeks, increased if tolerated to 9.5 mg/24 hours daily for a further 6 months, then increased if necessary to 13.3 mg/24 hours daily, increase to 13.3 mg/24 hours patch if well tolerated and cognitive deterioration or functional decline demonstrated; use caution in patients with body-weight less than 50 kg, if treatment interrupted for more than 3 days, retitrate from 4.6 mg/24 hours patch.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild to moderate dementia in Parkinson's disease</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily, dose to be increased at intervals of at least 2 weeks according to response and tolerance; usual dose 3&#8211;6 mg twice daily (max. per dose 6 mg twice daily), if treatment interrupted for more than several days, retitrate from 1.5 mg twice daily.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>When switching from oral to transdermal therapy, patients taking 3&#8211;6&#8239;mg by mouth daily should initially switch to 4.6&#8239;mg/24&#8239;hours patch, then titrate as above. Patients taking 9&#8239;mg by mouth daily should switch to 9.5&#8239;mg/24 hours patch if oral dose stable and well tolerated; if oral dose not stable or well tolerated. patients should switch to 4.6&#8239;mg/24&#8239;hours patch, then titrate as above. Patients taking 12&#8239;mg by mouth daily should switch to 9.5&#8239;mg/24 hours patch. The first patch should be applied on the day following the last oral dose </p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterases.</p>
            </section>
      </section>


      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Titrate according to individual tolerability in mild to moderate impairment.</p>
            </section>
            <section class="generalInformation">
              <p>Use with caution in severe impairment&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Titrate according to individual tolerability.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, agitation, anorexia, anxiety, bradycardia, confusion, diarrhoea, dizziness, drowsiness, dyspepsia, extrapyramidal symptoms, headache, increased salivation, insomnia, malaise, nausea, sweating, tremor, urinary incontinence, vomiting, weight loss, worsening of Parkinson&#8217;s disease,
              </p>
              <p>
                <strong>uncommon:</strong> Atrial fibrillation, AV block, depression, syncope,
              </p>
              <p>
                <strong>rare:</strong> Angina, duodenal ulceration, gastric ulceration, rash, seizures,
              </p>
              <p>
                <strong>veryRare:</strong> Gastro-intestinal haemorrhage, hallucinations, hypertension, pancreatitis, tachycardia,
              </p>
              <p>
                <strong>notKnown:</strong> Aggression, dehydration, hepatitis, restlessness, sick sinus syndrome, skin hypersensitivity reactions,
              </p>
        
        
            <section class="advice">
              <p>Transdermal administration less likely to cause gastro-intestinal disturbance.</p><p>Treatment should be interrupted if gastro-intestinal side-effects occur and withheld until their resolution&#8212;retitrate dose if necessary.</p><p>Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use</h3>
              <p>Apply patches to clean, dry, non-hairy, non-irritated skin on back, upper arm, or chest, removing after 24 hours and siting a replacement patch on a different area (avoid using the same area for 14 days).</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA217</h3>
              <p outputclass="title">Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease (March 2011)</p> <p>Rivastigmine can be used for the treatment of mild to moderate Alzheimer&#8217;s disease. Treatment should only be prescribed under the following conditions:</p> <ul> <li>Alzheimer's disease must be diagnosed and treatment initiated by a specialist; treatment can be continued by general practitioners under a shared-care protocol;</li> <li>the carer's view of the condition should be sought before and during treatment;</li> <li>treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.</li> </ul> <p>Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer&#8217;s disease when the patient has learning or other disabilities, or other communication difficulties.</p><xref format="html" href="http://www.nice.org.uk/TA217">www.nice.org.uk/TA217</xref>
                <a href="http://www.nice.org.uk/TA217" target="_blank">www.nice.org.uk/TA217</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Bladder outflow obstruction
          </li>
          <li>
            conduction abnormalities
          </li>
          <li>
            duodenal ulcers
          </li>
          <li>
            gastric ulcers
          </li>
          <li>
            history of asthma
          </li>
          <li>
            history of chronic obstructive pulmonary disease
          </li>
          <li>
            history of seizures
          </li>
          <li>
            risk of fatal overdose with patch administration errors
          </li>
          <li>
            sick sinus syndrome
          </li>
          <li>
            susceptibility to ulcers
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor body-weight.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RIVASTIGMINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76526"><a href="../medicinalForm/PHP76526.html" data-target="#PHP76526" data-action="load">Capsule</a></div>
            <div id="PHP76533"><a href="../medicinalForm/PHP76533.html" data-target="#PHP76533" data-action="load">Oral solution</a></div>
            <div id="PHP76540"><a href="../medicinalForm/PHP76540.html" data-target="#PHP76540" data-action="load">Transdermal patch</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
